ArticleJournal of clinical medicine2020
On-Treatment Decrease of Serum Interleukin-6 as a Predictor of Clinical Response to Biologic Therapy in Patients with Inflammatory Bowel Diseases.
Article in Journal of clinical medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 46 citations in OpenAlex.
- A Randomized Controlled Pilot Study Evaluating the Safety and Efficacy of Nifuroxazide in Patients with Ulcerative Colitis.Drug design, development and therapy · 2025Trial
- Serum leucine-rich α-2-glycoprotein and monocyte chemoattractant protein-1 as novel biomarkers for predicting vedolizumab response in patients with ulcerative colitis.Crohn's & colitis 360 · 2026Article
- Modulation of mTOR, NLRP3, and Nrf2/HO-1 signaling by atorvastatin and nitazoxanide in experimental ulcerative colitis.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Ulcerative colitis, pathophysiological mechanisms and drug repurposing: a new therapeutic dawn-narrative review.Inflammopharmacology · 2026Review
- Serum superoxide dismutase (SOD), malondialdehyde (MDA), IL-6, IL-8, TNF-a, serum immune markers after allogeneic blood transfusion in patients with gastrointestinal bleeding.Journal of medical biochemistry · 2026Article
- AQP9 and IFITM1 as drivers of immune infiltration and tumor progression in IBD-associated colorectal cancer: from computational insights to experimental validation.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Serum cytokine inflammatory profile in children with ulcerative colitis during 6-month follow-up.Scientific reports · 2025Article
- The importance of growth differentiation factor 15 and interleukin 6 serum levels in inflammatory bowel diseases.Journal of physiology and biochemistry · 2025Article
- Assessment of the Utility of Selected Inflammatory Markers in Correlation with Magnetic Resonance Enterography (MRE) Findings in the Diagnosis of Crohn's Disease.Biomolecules · 2025Article
- Therapeutic Drug Monitoring as a Tool for the Clinical Outcome Prediction in Vedolizumab-Treated Patients: An Italian Pilot Study.Biomedicines · 2024Article
- Effect of a high dose atorvastatin as adjuvant therapy to mesalamine in attenuating inflammation and symptoms in patients with ulcerative colitis: a randomized controlled pilot study.Frontiers in medicine · 2024Article
- Ulcerative Colitis-associated Spondyloarthritis Successfully Treated with Infliximab in the Absence of Enhanced TNF-α Responses.Internal medicine (Tokyo, Japan) · 2023Article
- Epidemiology of Inflammatory Bowel Diseases: A Population Study in a Healthcare District of North-West Italy.Journal of clinical medicine · 2023Article
- Personalized Treatment for Crohn's Disease: Current Approaches and Future Directions.Clinical and experimental gastroenterology · 2023Review
- Special Issue "Advances in Gastrointestinal and Liver Disease: From Physiological Mechanisms to Clinical Practice".Journal of clinical medicine · 2022Article
- Vitamin D-Related Genetics as Predictive Biomarker of Clinical Remission in Adalimumab-Treated Patients Affected by Crohn's Disease: A Pilot Study.Pharmaceuticals (Basel, Switzerland) · 2021Article
- Inositol-Requiring Kinase 1 Regulates Apoptosis via Inducing Endoplasmic Reticulum Stress in Colitis Epithelial Cells.Digestive diseases and sciences · 2021Article
- Serum inflammatory markers in the diagnosis and assessment of Crohn's disease activity.Archives of medical science : AMS · 2021Article
- Influence of Vitamin D3 Supplementation on Infliximab Effectiveness in Chinese Patients With Crohn's Disease: A Retrospective Cohort Study.Frontiers in nutrition · 2021Article
- Biomarkers of Crohn's Disease to Support the Development of New Therapeutic Interventions.Inflammatory bowel diseases · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In patients with inflammatory bowel diseases (IBD) undergoing biologic therapy, biomarkers of treatment response are still scarce. This study aimed to evaluate whether serum zonulin, a biomarker of intestinal permeability; soluble CD163 (sCD163), a macrophage activation marker; and a panel of serum cytokines could predict the response to biologic treatment in patients with IBD. For this purpose, we prospectively enrolled 101 patients with IBD and 19 patients with irritable bowel syndrome (IBS) as a control group; 60 out of 101 patients underwent treatment with biologics. Zonulin, sCD163, and cytokines were measured at the baseline in all patients and after 10 weeks of treatment in the 60 patients who underwent biologic therapy. We observed that zonulin levels were higher in IBD patients with active disease compared to those in remission (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.